Eric G. Devine, PhD

Assistant Professor, Psychiatry

Eric Devine
720 Harrison Ave


Eric Devine is the director of the Clinical Studies Unit in the Department of Psychiatry at Boston Medical Center. Dr. Devine serves as Vice-Chair for the Boston Medical Center and Boston University Medical Campus Institutional Review Board, and he is the Director of the IRB Internship training program. He teaches addiction treatment courses for the Mental Health Counseling and Behavioral Medicine Program at Boston University School of Medicine, and also for the BU School of Social Work Professional Education Program. Dr. Devine is a member of the Motivational Interviewing Network of Trainers (MINT). He has participated in numerous NIAAA and NIDA-funded multi-site trials testing medications for the treatment of substance use disorders and has had a role in two SAMHSA-funded grants focused on training and dissemination of SBIRT. Dr. Devine also had a role in the development of psychosocial treatments for addiction and has co-authored several treatment manuals and online behavioral platforms for use in multi-site trials testing medications for substance use disorders.

Special Interests: Medication development, clinical trials, psychosocial treatments for substance use disorder, motivational interviewing, cognitive behavioral therapy, universal screening for substance use, ethics of human subjects’ research, and manualized treatment approaches for substance use disorders.

Other Positions

  • Active Staff Hospital Privileges, Psychiatry, Boston Medical Center


  • Bowling Green State University, PhD
  • Bowling Green State University, MA
  • University of Wisconsin–Milwaukee, BA

Classes Taught

  • GMS MH 812
  • None


  • Published on 12/9/2018

    Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, Rosenthal RN, Dunn KE, Strain EC, Ray L, Shoptaw S, Ait-Daoud Tiouririne N, Gunderson EW, Ransom J, Scott C, Leggio L, Caras S, Mason BJ, Litten RZ. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Alcohol Clin Exp Res. 2019 Jan; 43(1):158-169. PMID: 30403402.

    Read at: PubMed
  • Published on 12/18/2016

    Devine EG, Peebles KR, Martini V. Strategies to exclude subjects who conceal and fabricate information when enrolling in clinical trials. Contemp Clin Trials Commun. 2017 Mar; 5:67-71. PMID: 29740622.

    Read at: PubMed
  • Published on 8/10/2016

    Devine EG, Ryan ML, Falk DE, Fertig JB, Litten RZ. An exploratory evaluation of Take Control: A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder. Contemp Clin Trials. 2016 Sep; 50:178-85. PMID: 27521807.

    Read at: PubMed
  • Published on 2/1/2015

    Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, Waters M, Richambault C. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015 Feb; 35(1):34-42. PMID: 25427171.

    Read at: PubMed
  • Published on 12/18/2014

    Devine, E. G., Knapp CM, Sarid-Segal, O, O’Keefe SO, Wardell C, Baskett M, Pecchia A, Ferrell, K, & Ciraulo, DA . Payment expectations for research participation among subjects who tell the truth, subjects who conceal information, and subjects who fabricate information. Contemporary Clinical Trials. 2014; (41):55-61.

  • Published on 12/18/2014

    Devine EG, Knapp CM, Sarid-Segal O, O'Keefe SM, Wardell C, Baskett M, Pecchia A, Ferrell K, Ciraulo DA. Payment expectations for research participation among subjects who tell the truth, subjects who conceal information, and subjects who fabricate information. Contemp Clin Trials. 2015 Mar; 41:55-61. PMID: 25530307.

    Read at: PubMed
  • Published on 5/1/2014

    DeMartini KS, Devine EG, DiClemente CC, Martin DJ, Ray LA, O'Malley SS. Predictors of pretreatment commitment to abstinence: results from the COMBINE study. J Stud Alcohol Drugs. 2014 May; 75(3):438-46. PMID: 24766756.

    Read at: PubMed
  • Published on 8/30/2013

    Ciraulo DA, Barlow DH, Gulliver SB, Farchione T, Morissette SB, Kamholz BW, Eisenmenger K, Brown B, Devine E, Brown TA, Knapp CM. The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders. Behav Res Ther. 2013 Nov; 51(11):729-35. PMID: 24055681.

    Read at: PubMed
  • Published on 7/18/2013

    Devine EG, Waters ME, Putnam M, Surprise C, O'Malley K, Richambault C, Fishman RL, Knapp CM, Patterson EH, Sarid-Segal O, Streeter C, Colanari L, Ciraulo DA. Concealment and fabrication by experienced research subjects. Clin Trials. 2013; 10(6):935-48. PMID: 23867223.

    Read at: PubMed
  • Published on 2/10/2012

    Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, A Tompkins D, Stout R. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012 Aug; 36(8):1421-30. PMID: 22324516.

    Read at: PubMed

View 8 more publications: View full profile at BUMC

View all profiles